Published in Clin Gastroenterol Hepatol on February 01, 2004
Preventing and treating hepatitis B infection. BMJ (2004) 1.80
Response to hepatitis B vaccination in patients with celiac disease. Dig Dis Sci (2007) 1.50
Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis (2006) 1.48
Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int (2007) 1.38
Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci (2005) 1.30
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut (2005) 1.28
The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis (2011) 1.17
Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob (2005) 1.11
A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) (2011) 1.04
Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study. Dig Dis Sci (2012) 0.89
Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci (2009) 0.88
Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol (2007) 0.88
DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol (2009) 0.87
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother (2006) 0.86
Management of HIV/HBV coinfection. MedGenMed (2006) 0.86
Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol (2006) 0.84
Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J (2007) 0.82
Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol (2016) 0.82
Characteristics of patients with chronic hepatitis-B virus infection in an urban hospital. J Natl Med Assoc (2007) 0.81
Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. Dig Dis Sci (2013) 0.81
A Practical Approach to Management of Chronic Hepatitis B. Int J Med Sci (2005) 0.81
Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy. Clin Mol Hepatol (2015) 0.80
Evaluation of the effects of oral N-acetylcysteine and a placebo in paraclinical and oxidative stress parameters of patients with chronic hepatitis B. Hepat Mon (2010) 0.78
Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. BMJ Open Gastroenterol (2015) 0.78
Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis (2009) 0.77
HBV and HCV therapy. Viruses (2009) 0.76
Treatment options for hepatitis B. Can J Infect Dis Med Microbiol (2007) 0.76
Screening in liver disease. World J Gastroenterol (2006) 0.76
A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice. PLoS One (2017) 0.75
High dose of Lamivudine and resistance in patients with chronic hepatitis B. Hepat Res Treat (2014) 0.75
Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int (2008) 0.75
Why adefovir is not yet available in Canada. Can J Gastroenterol (2006) 0.75
Resistance to lamivudine therapy: is there more than meets the eye? Gut (2005) 0.75
Trends in the indication and method of liver biopsy for hepatitis B and C. Dig Dis Sci (2010) 0.75
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Differentiation of the major Listeria monocytogenes serovars by multiplex PCR. J Clin Microbiol (2004) 4.32
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Wound healing recapitulates morphogenesis in Drosophila embryos. Nat Cell Biol (2002) 4.04
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol (2011) 3.66
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol (2011) 3.49
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int (2011) 3.36
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol (2005) 3.09
Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology (2008) 2.81
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
The role of social scientists in synthetic biology. Science & Society Series on Convergence Research. EMBO Rep (2009) 2.57
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. Am J Gastroenterol (2002) 2.55
Wound repair at a glance. J Cell Sci (2009) 2.53
Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun (2005) 2.52
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 2.49
Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration. J Cell Biol (2005) 2.38
New aspects regarding evolution and virulence of Listeria monocytogenes revealed by comparative genomics and DNA arrays. Infect Immun (2004) 2.31
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology (2007) 2.16
Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT. Am J Gastroenterol (2004) 2.12
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol (2006) 2.12
Dynamic analysis of dorsal closure in Drosophila: from genetics to cell biology. Dev Cell (2002) 2.06
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol (2014) 2.03
Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology (2006) 2.03
Dynamic analysis of filopodial interactions during the zippering phase of Drosophila dorsal closure. Development (2008) 2.03
Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol (2007) 2.02
Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med (2008) 1.99
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci (2004) 1.94
The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol (2011) 1.93
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology (2002) 1.88
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.85
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther (2010) 1.85
The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol (2007) 1.85
Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. Curr Biol (2012) 1.80
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study. Am J Clin Pathol (2012) 1.79
Imaging macrophage chemotaxis in vivo: studies of microtubule function in zebrafish wound inflammation. Cell Motil Cytoskeleton (2006) 1.79
Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis (2008) 1.78